Molly Gunn, now a 41-year-old mother of three living in Somerset, first tried magic mushrooms at age 23 when they were still legal in the early 2000s.. That experience ended with a woozy, cartoonish bad trip. Two decades later, a single drop of mushroom oil at a pool party in 2019 changed her perspective entirely, according to a report on her personal story. She now uses microdoses of psilocybin tinctures to reduce anxiety, feel more connected to her children and nature, and replace weeknight wine with what she calls a healthier alternative.

From a bad trip at 23 to microdosing at 41

The source report details how Gunn’s first encounter with magic mushrooms—purchased legally on Brick Lane in London—left her lying down with a friend’s face appearing “lurid green.” She dismissed mushrooms as a one-and-done experience for nearly two decades. But at a bank holiday barbecue in 2019, a friend offered her a drop of mushroom oil bought from a Glastonbury shaman. That tiny brown dot, licked off her hand and washed down with wine, produced a “hazy glow” rather than terror.

Gunn’s story illustrates a broader shift: the same substance that once caused her to swear off psychedelics is now a tool she uses to slow down. The report notes that she now knows her limits, having once taken too many drops at a mini festival where she had to be cared for by her husband like a “fourth child.”

Why ‘set and setting’ became her rule of thumb

Gunn reports that responsible microdosing hinges on environment: she only takes mushroom oil at home or at close friends’ houses, often while her children—ages 15, 12, and 8—are around or before watching TV. The reort quotes her as saying people talk about “set and setting” (who you are with and your location), and she finds the drops work best when she feels safe and relaxed.

She acknowledges that to outsiders, this use of a Class A illegal drug might seem reckless. But she insists she is a “switched-on mother” whose kids are happy and thriving. The report says her children know about her past habit, and she points to a growing community called Moms on Mushrooms in London, Bristol, and the United States that normalises microdosing among parents.

Mushroom oil versus weeknight wine: a health trade-off

The source report emphasises Gunn’s comparison between microdosing and alcohol. She argues that a drop of mushroom oil gives a nice buzz but is “far less potent” and healthier for the liver than a glass of wine. In the summer,she kept a bottle of the tincture handy to replace her evening drink, noting the irony that alcohol remains legal while psilocybin does not.

This perspective taps into a wider conversation among mental-health advocates about the comparative harms of legal and illegal substances. The report does not include medical or scientific experts,leaving the health claims solely based on Gunn’s personal testimony. Mothers are becoming “more informed about mental health and natural products that bring calm and reduce anxiety,” Gunn says in the report.

What the report leaves unanswered about safety and legality

While Gunn’s experience is positive, the source report does not address critical questions. It does not specify the dosage or concentration of the mushroom oil she used, nor does it mention any potential side effects beyond the single overdose episode at the festival. There is no independent verification of the product’s purity or consistency, and the shaman who sold the tincture remains unnamed.

Legally, psilocybin is a Class A drug in the UK, but the report does not explore enforcement or whether parents risk legal consequences when microdosing. Gunn herself raises the inconsistency of alcohol’s legality but does not offer a prescription for policy change. Readers are left to weigh her personal testimony against the backdrop of ongoing clinical trials on psychedelics for mental health—a tension the source report only hints at .

A quiet trend that mirrors broader psychedelic renaissance

Gunn’s story is not isolated. The report mentions a community called Moms on Mushrooms and a trend among midlife parents in London, Bristol, and the US. This echoes the wider revival of interest in psychedelics for therapeutic use, from ketamine clinics to FDA-backed psilocybin trials for depression. However, the report focuses on personal anecdote rather than scientific data, reflecting the disconnect between grassroots adoption and formal medical approval.

The source report does not provide statistics on how many parents microdose or whether there are any clinical studies supporting the subjective benefits Gunn describes. It remains unclear whether her approach is safe for long-term use or whether it could interfere with parenting duties—questions that future reporting will need to address.